125791-83-5

Basic information

• Product Name: 4-Mercapto-pentanoic acid
• Synonyms: 4-Mercapto-pentanoic acid
• CAS NO: 125791-83-5
• Molecular Formula: C₅H₁₀O₂S
• Molecular Weight: 134.2
• Product Categories: Miscellaneous
• Mol File: 125791-83-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Mercapto-pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Mercapto-pentanoic acid(125791-83-5)
• EPA Substance Registry System: 4-Mercapto-pentanoic acid(125791-83-5)

Safety Data

• Hazardous Substances Data: 125791-83-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Mercapto-pentanoic acid is used as a building block for the synthesis of pharmaceuticals, contributing to the development of various medicinal compounds.
Used in Agrochemical Production:
4-Mercapto-pentanoic acid is used as a precursor in the production of agrochemicals, aiding in the creation of substances that help protect and enhance crop yields.
Used in Flavor Industry:
4-Mercapto-pentanoic acid is used as a component in the synthesis of flavors, adding unique taste profiles to food and beverage products.
Used in Chemical Compound Production:
4-Mercapto-pentanoic acid is used as a building block in the production of various other chemical compounds, expanding its utility across different industries.
Used in Industrial Processes:
4-Mercapto-pentanoic acid is used as a metal complexing agent in some industrial processes, helping to bind and stabilize metal ions.
Used in Polymer Production:
4-Mercapto-pentanoic acid is used in the production of polymers, contributing to the development of new materials with specific properties.
Note: Due to its strong and unpleasant odor, 4-Mercapto-pentanoic acid has limited applications in products meant for personal care and household use.

Upstream product

• 123-76-2 levulinic acid 
• 773837-37-9 sodium cyanide 
• 107-80-2 1,3-dibromobutane 
• 17356-08-0 thiourea 
• 108-29-2 5-methyl-dihydro-furan-2-one 
• 14470-12-3 4-bromovalero-nitrile 
• 7647-01-0 hydrogenchloride 
• 5650-74-8 5-methyldihydrothiophen-2(3H)-one 
• 7732-18-5 water 
• 854658-71-2 4-acetylsulfanyl-valeric acid 

Downstream Products

• 663598-55-8 4-(5-Nitro-pyridin-2-yldithio)-pentanoic acid 
• 1613697-59-8 C₃₃H₃₀N₂O₇S₂ 
• 1613697-60-1 C₂₈H₄₀O₄S₂Si 
• 1613697-58-7 C₄₂H₅₀N₂O₇S₂Si 
• 1613697-57-6 C₄₅H₆₂N₁₀O₈S₃ 
• 1613697-63-4 C₂₇H₃₆N₄O₆S₂ 
• 1613697-50-9 C₄₁H₄₆N₆O₉S₂ 
• 1613697-62-3 C₂₃H₂₃NO₆S₂ 
• 1613697-49-6 C₆₂H₇₆N₂O₂₀S₂ 
• 1613697-61-2 C₁₉H₂₀O₄S₂ 

Relevant articles and documents

LIPID DERIVATIVES FOR IN VITRO OR IN VIVO DELIVERY

The present invention relates to novel constructs that allow for delivery of biologically active agents into cells. In certain embodiments, the constructs comprises conjugates of a lipophilic membrane dye, or a derivative or analogue thereof, with the biologically active agent.

METHODS FOR PREPARATION OF CYTOTOXIC CONJUGATES OF MAYTANSINOIDS AND CELL BINDING AGENTS

The Invention provides a method for producing a cytotoxic conjugate which comprises one or more maytansinoid molecules and a cell binding agent, said method consisting essentially of the single step of reacting one or more maytansinoid molecules containing a reactive ester with a cell binding agent.

THERAPEUTIC AGENT FOR TREATING TUMORS

The present disclosure relates to a therapeutic agent of the formula: Z-C(=O)-(CH2)n-?-S-S-(CRR')m-(CH2)p-C(=O)- NH-(CH2)q-NH-Y[NH-(CH2)r-X-T-W][NH-(CH2-CH-O)t (CH2)s-NH-V] Formula I or a pharmaceutically acceptable salt thereof, useful for treating tumors, including cancers. Where the compound of Formula I also contains a radionuclide or an imaging agent or both, the compound of formula I is a theranostic agent useful for treating and diagnosing tumors, including cancers.

ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN

The present disclosure provides derivatives of abiraterone, non-covalently bound complexes of the abiraterone derivatives with serum albumin, pharmaceutical compositions of the same, and methods of use thereof. The non-covalently bound complexes are significantly more water-soluble than abiraterone and are useful for the treatment of a disease or condition that can benefit from CYP17 inhibition, such as prostate cancer.

Design, synthesis, and biological evaluations of tumor-targeting dual-warhead conjugates for a taxoid-camptothecin combination chemotherapy

Novel tumor-targeting dual-warhead conjugates, 2 (DW-1) and 3 (DW-2), which consist of a next-generation taxoid, 1 (SB-T-1214), and camptothecin as two warheads, self-immolative disulfide linkers for drug release, biotin as the tumor-targeting moiety, and 1,3,5-triazine as the tripod splitter module, were designed and synthesized. The potency of 2 was evaluated against MX-1, MCF-7, ID8, L1210FR (BR+, biotin receptor overexpressed) and WI38 (BR-, normal) cell lines in the absence and presence of glutathione (GSH), which is an endogenous thiol that triggers drug release inside the cancer cells. With the GSH and resuspension protocol, 2 exhibited IC50 values of 3.22-9.80 nM against all BR+ cancer cell lines, and 705 nM against WI38. Thus, there was a two orders of magnitude higher selectivity to cancer cells. Also, a clear cooperative effect was observed for the taxoid-camptothecin combination when two drugs were delivered to the cancer cells specifically in the form of a dual-warhead conjugate.

Targeted and armed oncolytic adenovirus via chemoselective modification

Oncolytic adenoviruses (Ads) are an emerging alternative therapy for cancer; however, clinical trial have not yet demonstrated sufficient efficacy. When oncolytic Ads are used in combination with taxoids a synergistic increase in both cytotoxicity and viral replication is observed. In order to generate a next generation oncolytic adenovirus, virion were physically conjugated to a highly potent taxoid, SB-T-1214, and a folate targeting motif. Conjugation was enabled via the metabolic incorporation of non-canonical monosaccharides (O-GlcNAz) and amino acids (homopropargylglycine), which served as sites for chemoselective modification.

Semisynthetic Maytansine analogues for the targeted treatment of cancer

Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.

STABILIZED APTAMERS TO PSMA AND THEIR USE AS PROSTATE CANCER THERAPEUTICS

The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX? method with 2'-O-methyl substituted nucleic acids, and cell surface SELEX? are described herein. Also included are methods and compositions for the treatment and diagnosis of disease characterized by PSMA expression, using the described nucleic acid ligands.

Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

The present invention discloses a one-step process for the production of cytotoxic conjugates of maytansinoids and cell binding agents. Maytansinoids having a disulfide linker that bears a reactive moiety are linked to cell binding agents, such as antibodies, without prior modification of the cell binding agent. These conjugates are useful as therapeutic agents which are delivered specifically to target cells and are cytotoxic.